

# 1 Herd immunity thresholds for SARS-CoV-2 estimated from 2 unfolding epidemics

3 Ricardo Aguas<sup>1</sup>, Guilherme Gonçalves<sup>2</sup>, Marcelo U. Ferreira<sup>3</sup>, M. Gabriela M.  
4 Gomes<sup>4,5\*</sup>

5 <sup>1</sup> *Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine,*  
6 *University of Oxford, Oxford, United Kingdom.*

7 <sup>2</sup> *Unidade Multidisciplinar de Investigação Biomédica, Instituto de Ciências*  
8 *Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal.*

9 <sup>3</sup> *Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil.*

10 <sup>4</sup> *Department of Mathematics and Statistics, University of Strathclyde, Glasgow,*  
11 *United Kingdom.*

12 <sup>5</sup> *Centro de Matemática e Aplicações, Faculdade de Ciências e Tecnologia,*  
13 *Universidade Nova de Lisboa, Caparica, Portugal.*

14

15 \* Correspondence and requests for materials should be addressed to M.G.M.G. (email:  
16 [gabriela.gomes@strath.ac.uk](mailto:gabriela.gomes@strath.ac.uk)).

17 **Variation in individual susceptibility or frequency of exposure to infection**  
18 **accelerates the rate at which populations acquire immunity by natural infection.**  
19 **Individuals that are more susceptible or more frequently exposed tend to be**  
20 **infected earlier and hence more quickly selected out of the susceptible pool,**  
21 **decelerating the incidence of new infections as the epidemic progresses.**  
22 **Eventually, susceptible numbers become low enough to prevent epidemic growth**  
23 **or, in other words, the herd immunity threshold (HIT) is reached. We have**  
24 **recently proposed a method whereby mathematical models, with gamma**  
25 **distributions of susceptibility or exposure to SARS-CoV-2, are fitted to epidemic**  
26 **curves to estimate coefficients of individual variation among epidemiological**  
27 **parameters of interest. In the initial study we estimated HIT around 25-29% for**  
28 **the original Wuhan virus in England and Scotland. Here we explore the limits of**  
29 **applicability of the method using Spain and Portugal as case studies. Results are**  
30 **robust and consistent with England and Scotland, in the case of Spain, but fail in**  
31 **Portugal due to particularities of the dataset. We describe failures, identify their**  
32 **causes, and propose methodological extensions.**

### 33 **Introduction**

34 Selection acting on unmeasured individual variation is a well-known source of bias in  
35 the analysis of populations. It has been shown to affect measured rates of mortality  
36 (Keyfitz and Littman; Vaupel et al 1979; Vaupel and Yashin 1985), the survival of  
37 endangered species (Kendall and Fox 2002; Jenouvrier et al 2018), the scope of  
38 neutral theories of biodiversity and molecular evolution (Steiner and Tuljapurkar  
39 2012, Gomes et al 2019), the measured risk of diseases whether non-communicable  
40 (Aalen et al 2015; Stensrud and Valberg 2017) or infectious (Anderson et al 1986;  
41 Dwyer et al 1997; Smith et al 2005; Bellan et al 2015; Gomes et al 2019; Corder et al  
42 2020; Montalbán et al 2020), and the efficacy of interventions such as vaccines  
43 (Halloran et al 1996; O’Hagan et al 2012; Gomes et al 2014; Gomes et al 2016;  
44 Langwig et al 2017) or symbionts (Pessoa et al 2016; King et al 2018). Building on  
45 this knowledge, we previously addressed how selection on individual variation might  
46 affect the course of the coronavirus disease (COVID-19) pandemic (Gomes et al  
47 2022).

48 COVID-19 is an infectious respiratory disease caused by a virus (severe acute  
49 respiratory syndrome coronavirus 2 [SARS-CoV-2]), which was first identified in  
50 China in late 2019 and has since spread worldwide leading to considerable human  
51 suffering and social disruption. European and American continents have been the  
52 most affected, with 0.16% and 0.20% of the respective total populations having died  
53 as of the 15 July 2021 (WHO 2021). Here we analyse series of daily deaths attributed  
54 to COVID-19 in Spain and Portugal (Iberian Peninsula) to study how individual  
55 variation in susceptibility and exposure to a respiratory virus affects its epidemic  
56 trajectory. Besides adding to the compendium of neglected effects of selection in

57 population dynamics we hope to stimulate a new approach to study epidemic  
58 dynamics.

59 The essence to the approach is that individual variation in susceptibility or exposure  
60 (connectivity) accelerates the acquisition of immunity in populations. More  
61 susceptible and more connected individuals have a higher propensity to be infected  
62 and thus are likely to become immune earlier. Due to this selective immunization by  
63 natural infection, heterogeneous populations acquire herd immunity more efficiently  
64 than suggested by models that do not fully account for these types of variation. Here  
65 we integrate a continuous distribution of susceptibility or connectivity in an otherwise  
66 basic COVID-19 epidemiological model, which necessarily accounts for non-  
67 pharmaceutical intervention effects, and generate three types of results. First, at  
68 national levels the herd immunity threshold by natural infection declines from around  
69 70% to 20-30%. This is newly reported here for Spain and in agreement with recent  
70 estimates for England and Scotland (Gomes et al 2022). Second, these inferences can  
71 be made relatively early in the pandemic, such as between first and second waves,  
72 provided the first wave is sufficiently large and spatially synchronous. Third, we  
73 include a selection of results for Portugal to illustrate how the inferential procedure  
74 degenerates when national data do not meet certain conditions.

## 75 **Individual variation in SARS-CoV-2 transmission**

76 SARS-CoV-2 is transmitted primarily by respiratory droplets and modelled as a  
77 susceptible-exposed-infectious-recovered (SEIR) process.

78 *Variation in susceptibility to infection*

79 Individual variation in susceptibility is integrated as a continuously distributed factor  
80 that multiplies the force of infection upon individuals (Diekmann et al 1990) in the  
81 form of an infinite system of ordinary differential equations (ODEs):

$$82 \quad \dot{S}(x) = -\lambda x S(x), \tag{1}$$

$$83 \quad \dot{E}(x) = \lambda x [S(x) + \sigma R(x)] - \delta E(x), \tag{2}$$

$$84 \quad \dot{I}(x) = \delta E(x) - \gamma I(x), \tag{3}$$

$$85 \quad \dot{R}(x) = (1 - \phi)\gamma I(x) - \sigma \lambda x R(x), \tag{4}$$

86 where  $S(x)$  is the density of individuals with susceptibility  $x$ ,  $E(x)$  and  $I(x)$  are the  
87 densities of individuals who originally had susceptibility  $x$  and became exposed and  
88 infectious, while  $R(x)$  represents those who have recovered and have their  
89 susceptibility reduced to a reinfection factor  $\sigma$  due to acquired immunity. Parameter  $\delta$   
90 is the rate of progression from exposed to a period of maximal infectiousness (=   
91 1/5.5 per day [McAloon et al. 2020; Lauer et al. 2020]),  $\gamma$  is the rate of recovery  
92 from maximal infectiousness (= 1/4 per day [Nishiura et al. 2020; Li et al. 2020]),  $\phi$   
93 is the proportion of individuals who die as a result of infection (= 0.008 [Pastor-  
94 Barriuso et al. 2021]), and:

$$95 \quad \lambda = \frac{\beta}{N} \int \rho E(y) + I(y) dy \tag{5}$$

96 is the average force of infection upon susceptible individuals in a population of  
97 approximately constant size  $N$  and transmission coefficient  $\beta$ . Standardizing so that  
98 susceptibility distributions have mean  $\int x g(x) dx = 1$ , given a probability density  
99 function  $g(x)$ , the basic reproduction number, defined as the expected number of  
100 secondary infections generated by an infected individual in a population that has no  
101 specific immunity to the virus (Diekmann et al 1990), is:

$$102 \quad \mathcal{R}_0 = \beta \left( \frac{\rho}{\delta} + \frac{1}{\gamma} \right), \quad (6)$$

103 where  $\rho$  is a factor measuring the infectiousness of individuals in compartment  $E$  in  
104 relation to those in  $I$  ( $= 0.5$  [Wei et al. 2020; To et al. 2020; Arons et al. 2020; He et  
105 al. 2020]). The coefficient of variation (CV) in individual susceptibility  $\nu =$   
106  $\sqrt{\int (x - 1)^2 g(x) dx}$  is also treated as a parameter.

107 The basic reproduction number  $\mathcal{R}_0$  is a theoretical framework. It is usually estimated  
108 from the initial growth in case numbers. However, as the virus spreads through the  
109 population, infected and immune individuals accumulate, reducing the availability of  
110 susceptible hosts. As a result, growth in case numbers deviates from being a direct  
111 indication of  $\mathcal{R}_0$  but rather of a so-called effective reproduction number  $\mathcal{R}_{eff}$ .

112 When susceptibility is given by a gamma distribution and acquired immunity is  
113 totally protective ( $\sigma = 0$ ), the effective reproduction number is:

$$114 \quad \mathcal{R}_{eff}(t) = \mathcal{R}_0 \left( \frac{S(t)}{N} \right)^{1+\nu^2}, \quad (7)$$

115 where  $S(t) = \int S(x, t) dx$  is the total number of susceptible individuals at time  $t$ , and  
116 (Equations 1-4) reduce exactly to a finite system of ODEs:

$$117 \quad \dot{S} = -\beta(\rho E + I) \left( \frac{S}{N} \right)^{1+\nu^2}, \quad (8)$$

$$118 \quad \dot{E} = \beta(\rho E + I) \left( \frac{S}{N} \right)^{1+\nu^2} - \delta E, \quad (9)$$

$$119 \quad \dot{I} = \delta E - \gamma I, \quad (10)$$

$$120 \quad \dot{R} = (1 - \phi)\gamma I, \quad (11)$$

121 where  $S$ ,  $E$ ,  $I$  and  $R$  are the total numbers of susceptible, exposed, infectious and  
122 recovered individuals, respectively (Novozhilov 2008; Montalbán et al. 2020).

123 *Variation in connectivity*

124 In a directly transmitted infectious disease, such as COVID-19, variation in exposure  
125 to infection is governed primarily by patterns of connectivity among individuals. Here  
126 we incorporate this in the system (Equations 1-4) under the assumption that  
127 individuals mix at random (Pastor-Satorras and Vespignani 2001; Miller et al. 2012),  
128 while in Supplementary Information we conduct some sensitivity analyses to this  
129 assumption. Under random mixing and heterogeneous connectivity, the force of  
130 infection is written as:

131 
$$\lambda = \frac{\beta \int y[\rho E(y) + I(y)] dy}{N \int yg(y) dy}, \quad (12)$$

132 and the basic reproduction number is:

133 
$$\mathcal{R}_0 = (1 + \nu^2)\beta \left( \frac{\rho}{\delta} + \frac{1}{\gamma} \right). \quad (13)$$

134 In this setup, when connectivity is given by a gamma distribution and acquired  
135 immunity is totally protective, the effective reproduction number is approximated by:

136 
$$\mathcal{R}_{eff}(t) = \mathcal{R}_0 \left( \frac{S(t)}{N} \right)^{1+2\nu^2}, \quad (14)$$

137 and (Equations 1-4) reduce approximately to the finite system of ODEs:

138 
$$\dot{S} = -(1 + \nu^2)\beta(\rho E + I) \left( \frac{S}{N} \right)^{1+2\nu^2}, \quad (15)$$

139  $\dot{E} = (1 + \nu^2)\beta(\rho E + I) \left(\frac{S}{N}\right)^{1+2\nu^2} - \delta E,$  (16)

140  $\dot{I} = \delta E - \gamma I,$  (17)


141  $\dot{R} = (1 - \phi)\gamma I,$  (18)

142 where  $S, E, I$  and  $R$  are the total numbers of susceptible, exposed, infectious and  
 143 recovered individuals, respectively (Montalbán et al. 2020).

144 We have combined the basic models described by the reduced systems in Equations  
 145 8-11 and Equations 15-18 with non-pharmaceutical interventions (NPIs) to produce  
 146 COVID-19 transmission models. We then estimate the relevant parameters for those  
 147 models by fitting to data series of daily deaths from each of the study countries.

148 **Non-pharmaceutical interventions and other transmissibility modifiers**

149 NPIs designed to control transmission typically reduce  $\beta$  and hence  $\mathcal{R}_0$ . Denoting the  
 150 time-dependent reproduction number when control measures are in place by  $\mathcal{R}_c(t)$ ,  
 151 the modified effective reproduction number is obtained by replacing  $\mathcal{R}_0$  with  $\mathcal{R}_c(t)$  in  
 152 (Equation 7) and (Equation 14) as appropriate. For the estimation of  $\mathcal{R}_c(t)$  we  
 153 introduce flexible transmissibility profiles  $c(t)$  as illustrated in Figure 1.



154



155 **Figure 1: Transmissibility profile.** Schematic illustration of factor  $c(t)$  representing  
 156 the combined effects of NPIs, seasonality and viral evolution on the reproduction  
 157 number  $\mathcal{R}_c(t)$ .  $T_0$  is the time when  $\mathcal{R}_c$  begins to decrease due to behavioural change  
 158 or seasonality (estimated);  $T_1 (> T_0)$  is the day first lockdown begins (informed by  
 159 data);  $c_1 \leq 1$  is the average  $c(t)$  achieved during the first lockdown;  $L_1, L_2$  and  $L_3$ ,  
 160 denote the length in days of the successive periods of strictest NPI measures ( $L_1$  being  
 161 the first lockdown). These profiles are adopted in fits until: 1 July 2020 (top); 1  
 162 March 2021 (bottom).

163 *One-wave transmissibility profile*

164 When the model is applied to the first pandemic wave only (until 1 July 2020) we use  
 165 the top profile in Figure 1.  $T_0$  is the time when  $\mathcal{R}_0$  begins to decrease due to  
 166 behavioural changes or seasonality;  $T_1 (> T_0)$  is the day first lockdown begins  
 167 (transmission is allowed to decrease between  $T_0$  and  $T_1$ );  $c_1 \leq 1$  is the average  $c(t)$   
 168 from the beginning of the first lockdown onwards (14 March in Spain, 19 March in  
 169 Portugal). Mathematically this is constructed as:

$$170 \quad c(t) = \begin{cases} 1, & \text{if } 0 < t \leq T_0, \\ 1 - (1 - c_1) \cdot \frac{t - T_0}{T_1 - T_0}, & \text{if } T_0 < t \leq T_1, \\ c_1, & \text{otherwise.} \end{cases} \quad (19)$$

171 *Two-wave transmissibility profile*

172 Applying the model over longer periods which capture multiple waves and multiple  
 173 lockdowns requires additional features on the transmissibility profile. Denoting by  $L_1$   
 174 the duration of the first lockdown (29 days in Spain, 44 days in Portugal), we allow  
 175 restrictions to be progressively relaxed at the end of this period by letting transmission  
 176 begin a linear increase such that  $c(t)$  reaches 1 in  $T_2$  days, which may or may not be  
 177 within the range of the study. Changes in other factors that affect transmission (such  
 178 as seasonality or viral evolution) are inseparable from contact changes in this  
 179 framework and are also accounted for by  $c(t)$ . Mathematically this is constructed as:

$$180 \quad c_0(t) = \begin{cases} 1, & \text{if } 0 < t \leq T_0, \\ 1 - (1 - c_1) \cdot \frac{t - T_0}{T_1 - T_0}, & \text{if } T_0 < t \leq T_1, \\ c_1, & \text{if } T_1 < t \leq T_1 + L_1, \\ 1 - (1 - c_1) \cdot \frac{(T_1 + L_1 + T_2 - t)}{T_2}, & \text{otherwise.} \end{cases} \quad (20)$$

181 Second and third lockdowns in the autumn and winter season are implemented as a  
 182 further reduction in transmission (by factors  $c_2$  and  $c_3$ , respectively) over the  
 183 stipulated time periods ( $L_2$  and  $L_3$  in the bottom panel of Figure 1):

$$184 \quad c_{\text{Spain}}(t) = \begin{cases} c_2 \cdot c_0(t), & \text{if } t \in [26 \text{ October } 2020, 22 \text{ December } 2020], \\ c_3 \cdot c_0(t), & \text{if } t \text{ from } 7 \text{ January } 2021 \text{ onwards,} \\ c_0(t), & \text{otherwise;} \end{cases} \quad (21)$$

$$185 \quad c_{\text{Portugal}}(t) = \begin{cases} c_2 \cdot c_0(t), & \text{if } t \in [9 \text{ November } 2020, 21 \text{ December } 2020], \\ c_3 \cdot c_0(t), & \text{if } t \text{ from } 14 \text{ January } 2021 \text{ onwards,} \\ c_0(t), & \text{otherwise.} \end{cases} \quad (22)$$

186 In Spain, second and third lockdowns were effectively a single intervention, moderately  
 187 interrupted by a short relaxation over Christmas, and hence we assume  $c_2 = c_3$  in this  
 188 country. This is contrasted by Portugal where the third lockdown was much stricter than the  
 189 second and estimated independently.

## 190 **Herd immunity thresholds**

191 Individual variation in risk of acquiring infection is under selection by the force of  
 192 infection, whether individual differences are due to biological susceptibility,  
 193 exposure, or both. The most susceptible or exposed individuals are selectively  
 194 removed from the susceptible pool as they become infected and eventually recover  
 195 with immunity (some die), resulting in decelerated epidemic growth and accelerated  
 196 acquisition of immunity in the population. The herd immunity threshold (HIT) defines  
 197 the percentage of the population that needs to be immune to reverse epidemic growth

198 and prevent future waves. In the absence of NPIs or other transmissibility modifiers,  
 199 if individual susceptibility or connectivity is gamma-distributed and mixing is  
 200 random, basic HIT curves ( $\mathcal{H}$ ) can be derived analytically (Montalbán et al 2020)  
 201 from the model systems (Equations 1-4, with the respective forces of infections). In  
 202 the case of variation in susceptibility to infection we obtain

$$203 \quad \mathcal{H} = 1 - \left[ \frac{1 - \sigma R_0}{(1 - \sigma)R_0} \right]^{\frac{1}{1+\nu^2}}, \quad (23)$$


204 while variable connectivity results in a different exponent:

$$205 \quad \mathcal{H} = 1 - \left[ \frac{1 - \sigma R_0}{(1 - \sigma)R_0} \right]^{\frac{1}{1+2\nu^2}}. \quad (24)$$

206 In less straightforward cases, such as when the characteristics follow a distribution  
 207 other than gamma (Gomes et al. 2022), when mixing is not random (Supplementary  
 208 Information), when both distributions in susceptibility and connectivity are  
 209 considered, or when contact networks are rewired as result of NPIs or otherwise,  $\mathcal{H}$   
 210 can be obtained numerically.

211 In the absence of reinfection ( $\sigma = 0$ ), both (Equation 23) and (Equation 24) convey  
 212 substantial declines in HIT as individual variation increases (Figure 2, Gomes et al.  
 213 2022 and Montalbán et al. 2020), most strikingly over relatively low CV (from  $\nu = 0$   
 214 up to 1 or 2). For concreteness, when  $\mathcal{R}_0 = 3$ ,  $\mathcal{H} = 67\%$  for  $\nu = 0$ , while  $\nu = 1$   
 215 brings  $\mathcal{H}$  down to 42% for heterogeneous susceptibility and 30% for heterogeneous  
 216 connectivity, and  $\nu = 2$  brings  $\mathcal{H}$  further down to 20% and 11%, respectively.  
 217 Accounting for reinfection ( $\sigma > 0$ ) might moderate these reductions. In any case,  
 218 such differences in HIT are an indication of strong sensitivity of the epidemic

219 dynamics to the parameter  $\nu$  over a range that appears realistic (Gomes et al. 2022).



220

221 **Figure 2: Herd immunity threshold and epidemic final size.** Herd immunity  
 222 thresholds (solid curves) are calculated according to (Equation 23) for heterogeneous  
 223 susceptibility and (Equation 24) for heterogeneous connectivity, assuming  $\mathcal{R}_0 = 3$  for  
 224 concreteness. Final sizes of the corresponding unmitigated epidemics are also shown  
 225 (dashed). Curves are generated for different values of the efficacy of immunity  
 226 conferred by natural infection ( $1 - \sigma$ ) as displayed in the legend: 100% (blue); 90%  
 227 (green); 80% (yellow); 70% (orange); 67% (corresponding to  $1 - 1/\mathcal{R}_0$  in this case;  
 228 red).

229 We emphasise, nevertheless, that  $\mathcal{H}$  is a theoretical framework to the extent that  $\mathcal{R}_0$  is  
 230 a theoretical framework. It cannot be measured directly when epidemic trajectories  
 231 are affected by interventions, but it can be inferred indirectly from epidemiological  
 232 data. By construction,  $\mathcal{H}$  changes if the parameters that determine its value change.  
 233 Most notably, natural changes in  $\mathcal{R}_0$  through time, which can happen due to seasonal  
 234 forces or viral evolution, transfer to  $\mathcal{H}$  according to (Equation 23), (Equation 24), or  
 235 even their homogeneity equivalent  $1 - 1/\mathcal{R}_0$ . As a result, the percentage of the  
 236 population immune required to prevent sustained epidemic growth may deviate from

237 the initial  $\mathcal{H}$ . Notwithstanding, a model with lower  $\mathcal{H}$  results in smaller epidemics  
238 than a model with higher  $\mathcal{H}$ , all non-basic processes being the same.

239 The phenomenon of variation and selection which accounts for lower HIT was widely  
240 explained around mid-2020 (Hartnett 2020) and generated broad public interest in the  
241 context of COVID-19. By early 2021, vaccines had become available, and a  
242 competing belief emerged to imply that the HIT might be unachievable for COVID-  
243 19 (Aschwanden 2021). While Hartnett (2020) writes about using the basic  $\mathcal{H}$  to  
244 assess pandemic potential, stressing how that is weakened by variation and selection  
245 by natural infection, Aschwanden (2021) focuses on the imperfect nature of both  
246 vaccine induced and natural immunity to endorse that reinfection may become  
247 frequent enough to make herd immunity unachievable. In the light of the theory  
248 presented here – specifically (Equation 23) and (Equation 24) – these views are  
249 orthogonal and do not contradict each other.

## 250 **Data**

251 We use publicly available epidemiological data from the coronavirus dashboards for  
252 Spain [<https://cnecovid.isciii.es/covid19>] and Portugal [<https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal>] to fit the models and estimate  
253 parameters of interest. Namely, we fit model reconstructed mortality timeseries  
254 assuming a fixed infection fatality ratio (IFR) to datasets containing daily deaths,  
255  $\{(k, y_k)\}_{k=0}^{n-1}$ , where  $k = 0$  is the day when the cumulative moving average of death  
256 numbers exceed  $5 \cdot 10^{-7}$  of the population (7 March in Spain, 19 March 2020 in  
257 Portugal).

259 Model fits were carried out to the raw series of daily deaths until the 1 July 2020 in

260 the first instance (to cover the first wave of the epidemic in the study countries), and  
261 until the 1 March 2021 in an extended analysis (as a compromise between having a  
262 series sufficiently long to capture much of the second wave and not so long that it  
263 would be affected by vaccination and require the vaccine to be modelled). We defined  
264 the initial conditions as:

$$265 \quad R(-\eta) = 0, \quad (25)$$

$$266 \quad I(-\eta) = \frac{y_0}{\phi[1 - \exp(-\gamma)]}, \quad (26)$$

$$267 \quad E(-\eta) = \frac{I(-\eta)}{1 - \exp(-\delta)}, \quad (27)$$

$$268 \quad S(-\eta) = N - E(-\eta) - I(-\eta) - R(-\eta), \quad (28)$$

269 where  $\eta$  is the excess duration of a fatal infection relative to non-fatal,  $y_0$  is the  
270 number of deaths in the first day of the study, and the population size  $N$  was obtained  
271 from the most recent respective censuses (approx. 46.94 million in Spain, 10.28  
272 million in Portugal, 3.57 million in the North Region of Portugal, 3.66 million in  
273 Lisbon and Tagus Valley Region of Portugal).

#### 274 **Model fitting and parameter estimating**

275 We assumed that reinfection was negligible throughout the study period. A study  
276 conducted in England (Hall et al. 2021), between June 2020 and January 2021,  
277 concluded that previous SARS-CoV-2 infection induced 84% effective immunity to  
278 future infections. In (Gomes et al. 2122) we fit models to daily COVID-19 deaths in  
279 England and Scotland, assuming no reinfection (i.e. 100% effective immunity) or  
280 90% effective immunity, and found it to have no significant effect on projected model

281 trajectories. Basically, the fit readjusts the parameters when reinfection is added to the  
 282 model in such a way that the HIT remains similar.

283 Parameter estimation was performed with the software MATLAB by employing a  
 284 multi-start local optimization approach followed by Markov chain Monte Carlo  
 285 (MCMC) posterior distribution sampling, using the PESTO (Parameter ESTimation  
 286 Toolbox) package (Stapor et al. 2018). We assumed the daily number of SARS-CoV-  
 287 2 infections to be Poisson distributed.

288 We approximate the dynamics of COVID-19 deaths by estimating the set of  
 289 parameters  $\theta$  that maximises the log-likelihood (LL) of observing the daily numbers  
 290 of reported deaths  $Y$ :

$$291 \quad LL(\theta|Y) = - \sum_{k=0}^{n-1} \tilde{y}(k, \theta) + \sum_{k=0}^{n-1} y(k) \ln(\tilde{y}(k, \theta)) - \sum_{k=0}^{n-1} \ln(y(k)!), \quad (29)$$

292 where  $\tilde{y}(k, \theta) = \phi\gamma I(k - \eta, \theta)$  are the simulated model output numbers of COVID-  
 293 19 deaths at day  $k$  for the set of parameters  $\theta$ ,  $Y = \{(k, y_k)\}_{k=0}^{n-1}$  are the numbers of  
 294 daily reported deaths, and  $n$  is the total number of days included in the analysis.

### 295 **Fitting models to one pandemic wave**

296 The models exploring heterogeneity in susceptibility (Equations 8-11) and  
 297 connectivity (Equations 15-18) both with transmissibility profile as in (Equation 19),  
 298 were fit to COVID-19 daily reported deaths in Spain and Portugal recorded until 1  
 299 July 2020. A homogeneous version obtained by setting  $\nu = 0$  in either model was  
 300 also fitted. Results for Spain are shown in Table 1 and Figure 3, and for Portugal in  
 301 Table 2 and Figure 4.

302 We estimate the basic reproduction number  $\mathcal{R}_0$  with 95% credible intervals (CI)  
303 around 3.5 – 3.8 in Spain and 2.3 – 3.4 in Portugal. For the minimal transmissibility  
304 factor  $c_1$  we estimate 0.21 – 0.27 when individual variation is allowed and 0.18 –  
305 0.19 with the homogeneity constraint in Spain, while in Portugal we estimate the  
306 wider intervals 0.26 – 0.39. For coefficients of variation in Spain, we estimate CV in  
307 the range 1.3 – 2.4 under heterogeneous susceptibility and 1.0 – 1.7 under  
308 heterogeneous connectivity. In Portugal, we obtain the much wider and uninformative  
309 ranges 0.0 – 3.2.

310 Left plots in Figures 3 and 4 show the best fitting model solutions generated from the  
311 median posterior estimates of each parameter in the respective countries as well as the  
312 95% CI generated from 100,000 posterior samples. The herd immunity thresholds  $\mathcal{H}$ ,  
313 calculated from  $\mathcal{R}_0$  and CV estimates, are  $\mathcal{H} = 19\%$  (95% CI, 13-32%) under  
314 heterogeneous susceptibility,  $\mathcal{H} = 19\%$  (95% CI, 13-36%) under heterogeneous  
315 connectivity, and  $\mathcal{H} = 72\%$  (95% CI, 71-73%) when homogeneity is imposed, in  
316 Spain. In Portugal, we obtain  $\mathcal{H} = 19\%$  (95% CI, 5-69%) under heterogeneous  
317 susceptibility,  $\mathcal{H} = 13\%$  (95% CI, 3-69%) under heterogeneous connectivity, and  
318  $\mathcal{H} = 67\%$  (95% CI, 66-69%) when homogeneity is imposed. Credible intervals for  
319  $\mathcal{H}$  in Portugal are wide and uninformative when individual variation is allowed which  
320 is expected given the wide ranges obtained for CV. NPIs in Portugal were initiated  
321 very early in the epidemic which resulted in transmissibility reductions blending with  
322  $\mathcal{R}_0$ , making parameter identification a major challenge from the data accessible to us.

323 In Spain, where the three models provide good fits to the data, model selection criteria  
324 such as AIC (Akaike information criterion) support the heterogeneous  
325 implementations. To better distinguish the various models, we run the respective



326 systems of equations forward, under a set of conventions, and compare the respective  
327 projected outcomes. Right plots in Figures 3 were generated by taking the end  
328 conditions of the left plots, moving all exposed and infectious individuals to  
329 recovered (except a residual proportion to seed a new outbreak) and running each  
330 model with the estimated  $\mathcal{R}_0$  and CV until the susceptible pool has been effectively  
331 depleted in all implementations. In this manner we can visualise how much more  
332 burden of infection appears to be ahead when models are constrained to be  
333 homogeneous (a manifestation of their relatively higher  $\mathcal{H}$ ). Roughly, epidemics peak  
334 one order of magnitude higher when models are homogeneous. This must have broad  
335 implications, which we believe remain largely unappreciated, for how a population  
336 will experience an epidemic, irrespective of how this basic scenario is adapted to  
337 specific factors such as behavioural patterns, seasonality, viral evolution, or  
338 vaccination.

339 The same analysis applied to Portugal, selects in favour of the homogeneity  
340 assumption and larger projected waves. We recall, however, the great uncertainty  
341 associated with these specific results. We investigate this further through fittings to  
342 longer data series, in the first instance.

343 **Table 1: Model parameters for Spain (one wave).** Estimated by Bayesian inference  
344 based on daily deaths until 1 July 2020. Model selection based on maximum log-  
345 likelihood (LL) and Akaike information criterion (AIC). Best fitting models have  
346 lower AIC scores (best in red, second best in blue). Herd immunity threshold ( $\mathcal{H}$ )  
347 derived from estimated  $\mathcal{R}_0$  and CV ( $\nu$ ).

|                             | Heterogeneous<br>susceptibility |                | Heterogeneous<br>connectivity |                | Homogeneous |                |
|-----------------------------|---------------------------------|----------------|-------------------------------|----------------|-------------|----------------|
|                             | Median                          | 95% CI         | Median                        | 95% CI         | Median      | 95% CI         |
| <i>Estimated parameters</i> |                                 |                |                               |                |             |                |
| $T_0$                       | 5.44                            | [3.52, 6.07]   | 5.40                          | [3.45, 6.07]   | 5.48        | [3.73, 6.04]   |
| $c_1$                       | 0.24                            | [0.21, 0.27]   | 0.24                          | [0.21, 0.28]   | 0.18        | [0.18, 0.19]   |
| $\eta$                      | 16*                             | [15.53, 16.47] | 16*                           | [15.52, 16.48] | 16*         | [15.52, 16.47] |
| $\mathcal{R}_0$             | 3.59                            | [3.51, 3.79]   | 3.59                          | [3.51, 3.80]   | 3.53        | [3.47, 3.71]   |
| $\nu$                       | 1.98                            | [1.33, 2.44]   | 1.41                          | [0.97, 1.74]   | 0           | -              |


| <i>Derived from estimated parameters</i> |                |            |                |            |                |            |
|--|----------------|------------|----------------|------------|----------------|------------|
| $\mathcal{H}$                            | 23%            | [17%, 38%] | 23%            | [16%, 37%] | 72%            | [71%, 73%] |
| <i>Model selection</i>                   |                |            |                |            |                |            |
| LL                                       | -503.78        |            | -503.50        |            | -518.33        |            |
| AIC                                      | <b>1017.60</b> |            | <b>1017.00</b> |            | <b>1044.70</b> |            |

348 \* Rounded median resulting in integer number of days.

349 **Table 2: Model parameters for Portugal (one wave).** Estimated by Bayesian  
350 inference based on daily deaths until 1 July 2020. Model selection based on maximum  
351 log-likelihood (LL) and Akaike information criterion (AIC). Best fitting models have  
352 lower AIC scores (best in red, second best in blue). Herd immunity threshold ( $\mathcal{H}$ )  
353 derived from estimated  $\mathcal{R}_0$  and CV ( $\nu$ ).

|  | Heterogeneous susceptibility |                | Heterogeneous connectivity |                | Homogeneous   |                |
|--|------------------------------|----------------|----------------------------|----------------|---------------|----------------|
|  | Median                       | 95% CI         | Median                     | 95% CI         | Median        | 95% CI         |
| <i>Estimated parameters</i>              |                              |                |                            |                |               |                |
| $T_0$                                    | 0.05                         | [0.00, 0.10]   | 0.05                       | [0.00, 0.10]   | 0.05          | [0.00, 0.10]   |
| $c_1$                                    | 0.31                         | [0.26, 0.36]   | 0.32                       | [0.26, 0.39]   | 0.31          | [0.26, 0.35]   |
| $\eta$                                   | 20*                          | [14.75, 25.72] | 20*                        | [13.27, 25.94] | 21*           | [15.56, 26.04] |
| $\mathcal{R}_0$                          | 2.62                         | [2.29, 3.21]   | 2.66                       | [2.27, 3.39]   | 2.61          | [2.28, 3.15]   |
| $\nu$                                    | 0.31                         | [0.01, 3.24]   | 0.38                       | [0.01, 3.04]   | 0             | -              |
| <i>Derived from estimated parameters</i> |                              |                |                            |                |               |                |
| $\mathcal{H}$                            | 58%                          | [7%, 69%]      | 53%                        | [4%, 70%]      | 62%           | [56%, 68%]     |
| <i>Model selection</i>                   |                              |                |                            |                |               |                |
| LL                                       | -287.10                      |                | -287.14                    |                | -287.34       |                |
| AIC                                      | <b>584.20</b>                |                | <b>584.28</b>              |                | <b>582.67</b> |                |


354 \* Rounded median resulting in integer number of days.



355

356 **Figure 3: Estimating SARS-CoV-2 transmission in Spain by fitting one wave of**  
 357 **COVID-19 deaths.** Variation in susceptibility (top panels); variation in connectivity  
 358 (middle panels); and homogeneous model (bottom panels). Susceptibility or  
 359 connectivity factors implemented as gamma distributions. Controlled ( $\mathcal{R}_c$ ) and  
 360 effective ( $\mathcal{R}_{eff}$ ) reproduction numbers are displayed on shallow panels underneath  
 361 the main plots. Basic reproduction number, coefficients of variation and

362 transmissibility profile parameters estimated by Bayesian inference as described in  
 363 Methods (estimates in Table 1). Curves represent model reconstructions from the  
 364 median posterior parameter estimates. Shades represent 95% credible intervals from  
 365 100,000 posterior samples.



366

367 **Figure 4: Estimating SARS-CoV-2 transmission in Portugal by fitting one wave of**  
368 **COVID-19 deaths.** Variation in susceptibility (top panels); variation in connectivity  
369 (middle panels); and homogeneous model (bottom panels). Susceptibility or  
370 connectivity factors implemented as gamma distributions. Controlled ( $\mathcal{R}_c$ ) and  
371 effective ( $\mathcal{R}_{eff}$ ) reproduction numbers are displayed on shallow panels underneath  
372 the main plots. Basic reproduction number, coefficients of variation and  
373 transmissibility profile parameters estimated by Bayesian inference as described in  
374 Methods (estimates in Table 2). Curves represent model reconstructions from the  
375 median posterior parameter estimates. Shades represent 95% credible intervals from  
376 100,000 posterior samples.

### 377 **Fitting models to two serial pandemic waves**

378 Here we take the models with heterogeneity in susceptibility (Equations 8-11) and  
379 connectivity (Equations 15-18) and apply the transmissibility profile in (Equations  
380 20-22) to both before fitting the model outputs to COVID-19 deaths recorded daily  
381 until 1 March 2021, in Spain and Portugal. As before a homogeneous version  
382 obtained by setting  $\nu = 0$  was also fitted. Results for Spain are shown in Table 3 and  
383 Figure 5, and for Portugal in Table 4 and Figure 6.

384 We estimate  $\mathcal{R}_0$  with 95% CI around 3.9 – 4.4 in Spain and 2.7 – 4.6 in Portugal.  
385 For the minimal transmissibility factor  $c_1$  we estimate 0.20 – 0.21 when individual  
386 variation is allowed and 0.17 with the homogeneity constraint in Spain, while in  
387 Portugal we obtain 0.23 – 0.32 with individual variation and 0.16 – 0.18 without. For  
388 coefficients of variation in Spain, we estimate CV around 2.0 under heterogeneous  
389 susceptibility and 1.3 under heterogeneous connectivity. In Portugal, the estimates are  
390 around 0.5.

391 Left plots in Figures 5 and 6 show best fitting model solutions as well as the  
392 respective 95% CI. In Spain, basic herd immunity thresholds calculated from best  
393 fitting  $\mathcal{R}_0$  and CV are  $\mathcal{H} = 25\%$  under heterogeneous susceptibility,  $\mathcal{H} = 27\%$   
394 under heterogeneous connectivity, and  $\mathcal{H} = 76\%$  when homogeneity is imposed. In

395 Portugal, we obtain again wider and higher ranges:  $\mathcal{H} = 56\%$  (95% CI, 52-57%)  
 396 under heterogeneous susceptibility,  $\mathcal{H} = 56\%$  (95% CI, 54-57%) under  
 397 heterogeneous connectivity, and  $\mathcal{H} = 77\%$  (95% CI, 76-78%) when homogeneity is  
 398 imposed.

399 Puzzling, as in the case of shorter data series, model selection supports the  
 400 homogeneous model for Portugal while still favouring the incorporation of individual  
 401 variation in Spain. Moreover, for each country, results are consistent whether we base  
 402 our estimates on one or two waves of the national epidemic. This consistency was  
 403 also verified in England and Scotland (Gomes et al 2022). This suggests that the  
 404 earlier initiation of NPIs may not fully explain why results for Portugal contrast with  
 405 those for other countries studied. In the next section we explore whether this may be  
 406 due to the asynchrony between the two largest regions (comprising approximately  
 407 66% of the total population), which could ultimately result in a mis-specified model  
 408 for this country.

409 **Table 3: Model parameters for Spain (two waves).** Estimated by Bayesian  
 410 inference based on daily deaths until 1 March 2021. Model selection based on  
 411 maximum log-likelihood (LL) and Akaike information criterion (AIC). Best fitting  
 412 models have lower AIC scores (best in red, second best in blue). Herd immunity  
 413 threshold ( $\mathcal{H}$ ) derived from estimated  $\mathcal{R}_0$  and CV ( $\nu$ ).


|  | Heterogeneous susceptibility |                  | Heterogeneous connectivity |                  | Homogeneous     |                  |
|--|------------------------------|------------------|----------------------------|------------------|-----------------|------------------|
|  | Median                       | 95% CI           | Median                     | 95% CI           | Median          | 95% CI           |
| <i>Estimated parameters</i>              |                              |                  |                            |                  |                 |                  |
| $T_0$                                    | 3.22                         | [3.18, 3.31]     | 6.06                       | [6.06, 6.07]     | 5.99            | [5.98, 5.99]     |
| $T_2$                                    | 448.42                       | [446.58, 452.53] | 429.91                     | [427.04, 433.98] | 783.88          | [777.04, 784.12] |
| $c_1$                                    | 0.20                         | [0.20, 0.20]     | 0.21                       | [0.21, 0.21]     | 0.17            | [0.17, 0.17]     |
| $c_2$                                    | 0.71                         | [0.71, 0.71]     | 0.68                       | [0.68, 0.68]     | 0.50            | [0.50, 0.50]     |
| $\eta$                                   | 12*                          | [12.42, 12.50]   | 12*                        | [11.54, 12.45]   | 10*             | [10.04, 10.07]   |
| $\mathcal{R}_0$                          | 4.36                         | [4.32, 4.37]     | 3.93                       | [3.92, 3.95]     | 4.11            | [4.10, 4.11]     |
| $\nu$                                    | 2.02                         | [2.01, 2.02]     | 1.30                       | [1.28, 1.31]     | 0               | -                |
| <i>Derived from estimated parameters</i> |                              |                  |                            |                  |                 |                  |
| $\mathcal{H}$                            | 25%                          | [25%, 25%]       | 27%                        | [27%, 27 %]      | 76%             | [76%, 76%]       |
| <i>Model selection</i>                   |                              |                  |                            |                  |                 |                  |
| LL                                       | -3511.40                     |                  | -3269.90                   |                  | -5826.40        |                  |
| AIC                                      | <b>7036.80</b>               |                  | <b>6553.90</b>             |                  | <b>11665.00</b> |                  |

414 \* Rounded median resulting in integer number of days.

415 **Table 4: Model parameters for Portugal (two waves).** Estimated by Bayesian  
 416 inference based on daily deaths until 1 March 2021. Model selection based on  
 417 maximum log-likelihood (LL) and Akaike information criterion (AIC). Best fitting  
 418 models have lower AIC scores (best in red, second best in blue). Herd immunity  
 419 threshold ( $\mathcal{H}$ ) derived from estimated  $\mathcal{R}_0$  and CV ( $\nu$ ).

|  | Heterogeneous susceptibility |                  | Heterogeneous connectivity |                  | Homogeneous    |                  |
|--|------------------------------|------------------|----------------------------|------------------|----------------|------------------|
|  | Median                       | 95% CI           | Median                     | 95% CI           | Median         | 95% CI           |
| <i>Estimated parameters</i>              |                              |                  |                            |                  |                |                  |
| $T_0$                                    | 0.03                         | [0.01, 0.05]     | 0.04                       | [0.00, 0.10]     | 0.05           | [0.00, 0.10]     |
| $T_2$                                    | 585.14                       | [573.66, 672.90] | 644.26                     | [615.71, 695.38] | 899.67         | [872.69, 946.07] |
| $c_1$                                    | 0.27                         | [0.27, 0.32]     | 0.24                       | [0.23, 0.25]     | 0.17           | [0.16, 0.18]     |
| $c_2$                                    | 0.71                         | [0.71, 0.87]     | 0.71                       | [0.70, 0.77]     | 0.66           | [0.64, 0.68]     |
| $c_3$                                    | 0.34                         | [0.27, 0.48]     | 0.42                       | [0.39, 0.48]     | 0.35           | [0.34, 0.36]     |
| $\eta$                                   | 16*                          | [15.52, 17.39]   | 14*                        | [12.76, 15.34]   | 12*            | [11.54, 12.33]   |
| $\mathcal{R}_0$                          | 2.94                         | [2.66, 2.96]     | 3.25                       | [3.14, 3.32]     | 4.36           | [4.20, 4.58]     |
| $\nu$                                    | 0.55                         | [0.54, 0.59]     | 0.47                       | [0.47, 0.49]     | 0              | -                |
| <i>Derived from estimated parameters</i> |                              |                  |                            |                  |                |                  |
| $\mathcal{H}$                            | 56%                          | [52%, 57%]       | 56%                        | [54%, 57%]       | 77%            | [76%, 78%]       |
| <i>Model selection</i>                   |                              |                  |                            |                  |                |                  |
| LL                                       | -1550.80                     |                  | -1376.80                   |                  | -1234.30       |                  |
| AIC                                      | <b>3117.50</b>               |                  | <b>2769.50</b>             |                  | <b>2482.50</b> |                  |

420 \* Rounded median resulting in integer number of days.




421

422 **Figure 5: Estimating SARS-CoV-2 transmission in Spain by fitting two serial**  
 423 **waves of COVID-19 deaths.** Variation in susceptibility (top panels); variation in  
 424 connectivity (middle panels); and homogeneous model (bottom panels). Susceptibility  
 425 or connectivity factors implemented as gamma distributions. Controlled ( $\mathcal{R}_c$ ) and  
 426 effective ( $\mathcal{R}_{eff}$ ) reproduction numbers are displayed on shallow panels underneath  
 427 the main plots. Basic reproduction number, coefficients of variation and



428 transmissibility profile parameters estimated by Bayesian inference as described in  
 429 Methods (estimates in Table 3). Curves represent model reconstructions from the  
 430 median posterior parameter estimates. Shades represent 95% credible intervals from  
 431 100,000 posterior samples.



432

433 **Figure 6: Estimating SARS-CoV-2 transmission in Portugal by fitting two serial**  
434 **waves of COVID-19 deaths.** Variation in susceptibility (top panels); variation in  
435 connectivity (middle panels); and homogeneous model (bottom panels). Susceptibility  
436 or connectivity factors implemented as gamma distributions. Controlled ( $\mathcal{R}_c$ ) and  
437 effective ( $\mathcal{R}_{eff}$ ) reproduction numbers are displayed on shallow panels underneath  
438 the main plots. Basic reproduction number, coefficients of variation and  
439 transmissibility profile parameters estimated by Bayesian inference as described in  
440 Methods (estimates in Table 4). Curves represent model reconstructions from the  
441 median posterior parameter estimates. Shades represent 95% credible intervals from  
442 100,000 posterior samples.

### 443 **Fitting models to regional data in Portugal**

444 Intrigued by the puzzling results for Portugal at country level, we gathered regional  
445 data. We found that the epidemic dynamics were considerably different between the  
446 two largest regions: North, home to roughly one third of the Portuguese population;  
447 and Lisbon and Tagus Valley, home to another third. Asynchrony of epidemic  
448 dynamics between regions of similar sizes may require disaggregated analyses. We  
449 then decided to fit the mortality data for the two regions simultaneously, estimating  
450 common parameters to describe country-wide lockdowns, and regions-specific  
451 parameters to describe the basic transmission dynamics ( $\mathcal{R}_0$  and CV). The results are  
452 provided in Tables 5, 6 and Figures 7-9. According to these analyses, the best-fitting  
453 models include heterogeneity.

454 Herd immunity thresholds inferred by fits to the longer series (until 1 March 2021)  
455 are around 25 – 34% in the North (similar as Spain, England and Scotland) and 47 –  
456 52% in Lisbon and Tagus Valley. The higher  $\mathcal{H}$  in the capital region results from the  
457 estimation of a lower CV. This may be real and due to the more urban character of  
458 Lisbon and Tagus Valley, or, in contrast, it may be a spurious result of the lack of a  
459 first wave in the region to inform the model. It would be interesting to replicate the  
460 regional analysis in other countries to investigate to what extent more urban regions

461 have higher HIT. As for the North,  $\mathcal{H}$  is much closer to that of Spain, England and  
462 Scotland, but slightly higher, nevertheless. This may also be a slightly spurious  
463 consequence of the first wave being more suppressed there (although not as much as  
464 in Lisbon and Tagus Valley) than in those other nations. Alternatively, there may be  
465 differences in reporting across countries (particularly those affecting whether deaths  
466 are declared with or from COVID-19 [Ferreira 2022; Gonçalves 2022]) influencing  
467 the accuracy of estimated model parameters.

468 Fits to the shorter series (until 1 July 2020) are again inconclusive. Not only the  
469 uncertainty around parameter estimates is large but some estimates are implausible.  
470 First,  $\mathcal{R}_0$  around 2 or less is on the low end of consensus estimates (Flaxman et al.  
471 2020; Keeling et al. 2020; Viana et al. 2021; Wood 2021). More strikingly, the  
472 algorithm is incapable of estimating CV from these regional series, resulting in  
473 convergence to the upper and lower limits of the prior distribution (uniform between  
474  $0.01 - \sqrt{12}$ ) in the North and Lisbon regions, respectively.

475 In summary, the results reported in this section support two notions. First,  
476 asynchronous dynamics may compromise parameter estimation based on model  
477 fittings to aggregated data. This should depend on whether the asynchrony in question  
478 is between similar-sized regions. Second, the early estimation of parameters for  
479 heterogeneous models (especially CV) may require a larger first wave than that  
480 required by models that are either homogeneous (Flaxman et al. 2020; Wood 2021) or  
481 have their heterogeneity informed directly by specific data (Keeling et al. 2020). The  
482 downside of these other approaches, however, is that heterogeneity is either absent or  
483 possibly incomplete, resulting in reduced selection and biased estimates. Among the

484 studies we have completed, England, Scotland and Spain had sufficiently sized first  
 485 waves to inform the inference of CV while Portugal did not.

486 **Table 5: Model parameters for the North and Lisbon regions of Portugal (one**  
 487 **wave).** Estimated by Bayesian inference based on daily deaths until 1 July 2020.  
 488 Model selection based on maximum log-likelihood (LL) and Akaike information  
 489 criterion (AIC). Best fitting models have lower AIC scores (best in red, second best in  
 490 blue). Herd immunity threshold ( $\mathcal{H}$ ) derived from estimated  $\mathcal{R}_0$  and CV ( $\nu$ ).

|                                | Heterogeneous susceptibility |                | Heterogeneous connectivity |                | Homogeneous |                |
|--------------------------------|------------------------------|----------------|----------------------------|----------------|-------------|----------------|
|                                | Median                       | 95% CI         | Median                     | 95% CI         | Median      | 95% CI         |
| <i>Common parameters</i>       |                              |                |                            |                |             |                |
| $T_0$                          | 0.05                         | [0.00, 0.10]   | 0.05                       | [0.00, 0.10]   | 0.05        | [0.00, 0.10]   |
| $c_1$                          | 0.48                         | [0.43, 0.52]   | 0.55                       | [0.47, 0.61]   | 0.43        | [0.40, 0.47]   |
| $\eta$                         | 24*                          | [19.45, 28.99] | 21*                        | [14.18, 27.37] | 29*         | [28.50, 28.50] |
| <i>North</i>                   |                              |                |                            |                |             |                |
| $\mathcal{R}_0$                | 2.17                         | [2.00, 2.45]   | 2.43                       | [2.17, 2.92]   | 1.91        | [1.80, 2.09]   |
| $\nu$                          | 3.44                         | [3.38, 3.46]   | 3.45                       | [3.39, 3.46]   | 0           | -              |
| $\mathcal{H}$                  | 5.9%                         | [5.2%, 7.0%]   | 3.5%                       | [3.0%, 4.4%]   | 48%         | [44%, 52%]     |
| <i>Lisbon and Tagus Valley</i> |                              |                |                            |                |             |                |
| $\mathcal{R}_0$                | 1.78                         | [1.65, 2.00]   | 1.65                       | [1.49, 1.96]   | 1.85        | [1.74, 2.02]   |
| $\nu$                          | 0.07                         | [0.01, 0.56]   | 0.07                       | [0.01, 0.57]   | 0           | -              |
| $\mathcal{H}$                  | 44%                          | [32%, 50%]     | 39%                        | [21%, 49%]     | 46%         | [43%, 51%]     |
| <i>Model selection</i>         |                              |                |                            |                |             |                |
| LL                             |                              | -520.56        |                            | -479.75        |             | -578.50        |
| AIC                            |                              | <b>1055.10</b> |                            | <b>973.49</b>  |             | <b>1167.00</b> |

491 \* Rounded median resulting in integer number of days.

492 **Table 6: Model parameters for the North and Lisbon regions of Portugal (two**  
 493 **waves).** Estimated by Bayesian inference based on daily deaths until 1 March 2021.  
 494 Model selection based on maximum log-likelihood (LL) and Akaike information  
 495 criterion (AIC). Best fitting models have lower AIC scores (best in red, second best in  
 496 blue). Herd immunity threshold ( $\mathcal{H}$ ) derived from estimated  $\mathcal{R}_0$  and CV ( $\nu$ ).


|                                | Heterogeneous susceptibility |                  | Heterogeneous connectivity |                  | Homogeneous |                  |
|--------------------------------|------------------------------|------------------|----------------------------|------------------|-------------|------------------|
|                                | Median                       | 95% CI           | Median                     | 95% CI           | Median      | 95% CI           |
| <i>Common parameters</i>       |                              |                  |                            |                  |             |                  |
| $T_0$                          | 0.06                         | [0.00, 0.10]     | 0.09                       | [0.06, 0.10]     | 0.05        | [0.03, 0.05]     |
| $T_2$                          | 498.77                       | [489.85, 515.47] | 499.41                     | [462.35, 547.99] | 960.64      | [960.28, 961.42] |
| $c_1$                          | 0.27                         | [0.26, 0.29]     | 0.25                       | [0.25, 0.25]     | 0.17        | [0.17, 0.17]     |
| $c_2$                          | 0.75                         | [0.73, 0.82]     | 0.71                       | [0.69, 0.75]     | 0.73        | [0.73, 0.73]     |
| $c_3$                          | 0.44                         | [0.42, 0.45]     | 0.49                       | [0.45, 0.50]     | 0.36        | [0.36, 0.36]     |
| $\eta$                         | 16*                          | [15.36, 16.46]   | 15*                        | [13.75, 15.16]   | 12*         | [11.62, 11.64]   |
| <i>North</i>                   |                              |                  |                            |                  |             |                  |
| $\mathcal{R}_0$                | 2.99                         | [2.88, 3.03]     | 3.12                       | [3.05, 3.18]     | 4.34        | [4.34, 4.35]     |
| $\nu$                          | 1.40                         | [1.39, 1.41]     | 0.99                       | [0.93, 1.20]     | 0           | -                |
| $\mathcal{H}$                  | 31%                          | [30%, 31%]       | 32%                        | [25%, 34%]       | 77%         | [77%, 77%]       |
| <i>Lisbon and Tagus Valley</i> |                              |                  |                            |                  |             |                  |

|                 |      |              |      |              |      |              |
|-----------------|------|--------------|------|--------------|------|--------------|
| $\mathcal{R}_0$ | 2.81 | [2.69, 2.86] | 2.95 | [2.87, 3.01] | 4.39 | [4.38, 4.40] |
| $\nu$           | 0.67 | [0.65, 0.70] | 0.54 | [0.53, 0.57] | 0    | -            |
| $\mathcal{H}$   | 51%  | [49%, 52%]   | 49%  | [47%, 51%]   | 77%  | [77%, 77%]   |

*Model selection*

|     |                |                |                |
|-----|----------------|----------------|----------------|
| LL  | -2313.50       | -2471.00       | -2764.30       |
| AIC | <b>4647.10</b> | <b>4961.90</b> | <b>5544.60</b> |


497 \* Rounded median resulting in integer number of days.



498

499 **Figure 7: Estimating SARS-CoV-2 transmission in the two larger regions of**  
500 **Portugal.** Heterogeneous susceptibility implemented as a gamma distribution.  
501 Controlled ( $\mathcal{R}_c$ ) and effective ( $\mathcal{R}_{eff}$ ) reproduction numbers are displayed on shallow  
502 panels underneath the main plots. Basic reproduction number, coefficients of  
503 variation and transmissibility profile parameters estimated by Bayesian inference as  
504 described in Methods (estimates in Table 5). Curves represent model reconstructions


505 from the median posterior parameter estimates. Shades represent 95% credible  
 506 intervals from 100,000 posterior samples.



507

508 **Figure 8: Estimating SARS-CoV-2 transmission in the two larger regions of**  
 509 **Portugal.** Heterogeneous connectivity implemented as a gamma distribution.  
 510 Controlled ( $\mathcal{R}_c$ ) and effective ( $\mathcal{R}_{eff}$ ) reproduction numbers are displayed on shallow  
 511 panels underneath the main plots. Basic reproduction number, coefficients of  
 512 variation and transmissibility profile parameters estimated by Bayesian inference as  
 513 described in Methods (estimates in Table 5). Curves represent model reconstructions

514 from the median posterior parameter estimates. Shades represent 95% credible  
 515 intervals from 100,000 posterior samples.



516

517 **Figure 9: Estimating SARS-CoV-2 transmission in the two larger regions of**  
 518 **Portugal.** Homogeneous model. Controlled ( $\mathcal{R}_c$ ) and effective ( $\mathcal{R}_{eff}$ ) reproduction  
 519 numbers are displayed on shallow panels underneath the main plots. Basic  
 520 reproduction number, coefficients of variation and transmissibility profile parameters  
 521 estimated by Bayesian inference as described in Methods (estimates in Table 5).  
 522 Curves represent model reconstructions from the median posterior parameter  
 523 estimates. Shades represent 95% credible intervals from 100,000 posterior samples.

524 **Discussion**

525 We fitted SEIR models, with inbuilt distributions of individual susceptibility or  
 526 exposure to infection, to daily series of COVID-19 deaths in Spain and Portugal. We  
 527 estimated relevant transmission parameters, such as the basic reproduction  
 528  $\mathcal{R}_0$ , and a time dependent transmissibility profile  $c(t)$  which multiplies  $\mathcal{R}_0$  to account  
 529 for effects of NPIs, seasonality, viral evolution, or any unexplicit factor that modifies

530 the ability of the virus to infect new hosts. In addition, as in (Gomes et al. 2022) we  
531 estimated coefficients of variation that characterise distributions of unmeasured  
532 individual susceptibility or connectivity.

533 The inference of selectable variation as presented here is uncommon in infectious  
534 disease modelling. Prior to attempting this in the context of the COVID-19 pandemic,  
535 we and others have conducted related studies in systems that were either  
536 experimentally controlled (Dwyer et al. 1997; Ben-Ami et al. 2008; Zwart et al. 2011;  
537 Pessoa et al. 2014; Langwig et al. 2017; King et al. 2018) or already endemic (Smith  
538 et al. 2005; Bellan et al. 2015; Corder et al. 2020). Several aspects of the pandemic  
539 made it more challenging. There was an urgency for early results from inherently  
540 scarce data, a challenge amplified by non-pharmaceutical interventions designed to  
541 suppress the epidemic. In countries where interventions began earlier (relative to the  
542 epidemic momentum), such as Portugal, it has been impossible to reach conclusive  
543 results without finer data and methods. In Spain (this study) and England and  
544 Scotland (Gomes et al 2022), on the other hand, interventions started later, and results  
545 were consistent, both internally and between each other. Our coefficients of variation  
546 for individual connectivity are similar to those measured directly by contact surveys  
547 (Gomes et al 2022).

548 Another group of authors highlighted the importance of considering the interplay  
549 between social dynamics and spread of infection when interpreting coefficients of  
550 variation (Tkachenko 2021). If society changed over time in such a way that  
551 individuals with low susceptibility/exposure in one wave became high  
552 susceptibility/exposure in a later wave, then coefficients of variation estimated from  
553 two-wave fits should be lower than those estimated from one-wave fits, resulting in



554 higher herd immunity thresholds. Our results for Spain are not indicative of this  
555 process playing a significant role in COVID-19. We estimate CV around 1.41 (95%,  
556 0.97 – 1.74) when we fit the first wave only, and 1.30 (95%, 1.28 – 1.31) when we  
557 fit two waves. The two-wave estimate is not significantly lower than that obtained  
558 from the one-wave analysis, suggesting that the postulated mechanism is not affecting  
559 our inferences. We saw the same consistency in our previous analysis of England and  
560 Scotland (Gomes et al. 2022). We find this unsurprising given the amply reported  
561 evidence of socioeconomic determinants as key drivers of heterogeneity in infectious  
562 diseases (e.g., Millett et al. 2020, Xia et al. 2022). Societal changes may not  
563 significantly impact our inferences unless major inversions in socioeconomic  
564 gradients had occurred which is unimaginable in the time scale of a pandemic. On the  
565 contrary, the opposite seems more plausible as more disadvantaged social groups  
566 suffer more from both disease and containment measures, exacerbating preexisting  
567 heterogeneity (Okonkwo et al. 2021).

568 The exploration presented here for Spain confirms recent findings for England and  
569 Scotland that the original SARS-CoV-2 had a herd immunity threshold in the range  
570 20-30%. The main specificity of the underlying studies is to include individual  
571 variation in susceptibility and exposure to infection in the set of model parameters  
572 being estimated. The modelling approach is relatively new, and its limits of  
573 applicability remain a subject for research and further methodological developments.  
574 Here we adopt a dataset from Portugal to highlight features that compromise the  
575 applicability of the basic method and, in some instances, propose refinements to push  
576 those limits.

577 **Acknowledgements**

578 We thank Rodrigo Corder, Jessica King and Antonio Montalbán for technical  
579 discussions and contributions to related research.

#### 580 **Author contributions**

581 M.G.M.G. conceived the study. R.A. and M.G.M.G. performed the analyses. All  
582 authors interpreted the data and wrote the paper.

#### 583 **Competing interests**

584 The authors declare no competing interests.

#### 585 **Data availability**

586 We used publicly available data from the coronavirus dashboards for Spain  
587 [<https://cneccovid.isciii.es/covid19>] and Portugal [[https://covid19.min-saude.pt/ponto-](https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal)  
588 [de-situacao-atual-em-portugal](https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal)]. Population sizes were obtained from recent censuses:  
589 46,771,836 for Spain; 10,196,709 for Portugal; 3,573,000 for Portugal-North; and  
590 3,447,173 for Lisbon and Tagus Valley.

591

#### 592 **References**

- 593 1. Keyfitz, N. & Littman, G. (1979) Mortality in a heterogeneous population. *Popul. Stud.*  
594 **33**, 333-342.
- 595 2. Vaupel, J., Manton, K. & Stallard, E. (1979) Impact of heterogeneity in individual frailty  
596 on the dynamics of mortality. *Demography* **16**, 439-454.
- 597 3. Vaupel, J., & Yashin, A. (1985) Heterogeneity ruses – some surprising effects of  
598 selection on population dynamics. *Am. Stat.* **39**, 176-185.
- 599 4. Kendall, B. E. & Fox, G. A. (2002) Variation among individuals and reduced  
600 demographic stochasticity. *Conserv. Biol.* **16**, 109-116.

- 601 5. Jenouvrier, S, Aubry, L. M., Barbraud, C, Weimerskirch, H & Caswell, H. (2018)  
602 Interacting effects of unobserved heterogeneity and individual stochasticity in the life  
603 history of the southern fulmar. *J. Anim. Ecol.* **87**, 212-222.
- 604 6. Steiner, U. K. & Tuljapurkar, S. (2012) Neutral theory for life histories and individual  
605 variability in fitness components. *Proc. Natl. Acad. Sci U. S. A.* **109**, 4684-4689.
- 606 7. Gomes, M. G. M., King, J. G., Nunes, A., Colegrave, N. & Hoffmann, A. (2019) The  
607 effects of individual nonheritable variation on fitness estimation and coexistence. *Ecol.*  
608 *Evol.* **16**, 8995-9004.
- 609 8. Aalen, O. O., Valberg, M., Grotmol, T. & Tretli, S. (2015) Understanding variation in  
610 disease risk: the elusive concept of frailty. *Int. J. Epidemiol.* **4**, 1408-1421.
- 611 9. Stensrud, M. J. & Valberg, M. (2017) Inequality in genetic cancer risk suggests bad  
612 genes rather than bad luck. *Nat. Commun.* **8**, 1165.
- 613 10. Anderson, R. M., Medley, G. F., May, R. M. & Johnson, A. M. (1986) A preliminary  
614 study of the transmission dynamics of the human immunodeficiency virus (HIV), the  
615 causative agent of AIDS. *IMA J. Math. Appl. Med. Biol.* **3**, 229-263.
- 616 11. Dwyer, G., Elkinton, J. S. & Buonaccorsi, J. P. (1997) Host heterogeneity in  
617 susceptibility and disease dynamics: Tests of a mathematical model. *Am. Nat.* **150**, 685-  
618 707.
- 619 12. Smith, D. L., Dushoff, J., Snow, R. W. & Hay, S. I. (2005) The entomological  
620 inoculation rate and *Plasmodium falciparum* infection in African children. *Nature* **438**,  
621 492-495.
- 622 13. Bellan, S. E., Dushoff, J., Galvani, A. P. & Meyers, L. A. (2015) Reassessment of HIV-1  
623 acute phase infectivity: accounting for heterogeneity and study design with simulated  
624 cohorts. *PLOS Med.* **12**, e1001801.
- 625 14. Gomes, M. G. M., et al. (2019) Introducing risk inequality metrics in tuberculosis policy  
626 development. *Nat. Commun.* **10**, 2480.

- 627 15. Corder, R. M., Ferreira, M. U. & Gomes, M. G. M. (2020) Modelling the epidemiology  
628 of residual *Plasmodium vivax* in a heterogeneous host population: a case study in the  
629 Amazon Basin. *PLOS Comput. Biol.* **16**, e1007377.
- 630 16. Halloran, M. E., Longini, I. M. Jr. & Struchiner, C. J. (1996) Estimability and  
631 interpretability of vaccine efficacy using frailty mixing models. *Am. J. Epidemiol.* **144**,  
632 83-97.
- 633 17. O'Hagan, J. J., Hernán, M. A., Walensky, R. P. & Lipsitch, M. (2012) Apparent  
634 declining efficacy in randomized trials: Examples of the Thai RV144 HIV vaccine and  
635 CAPRISA 004 microbicide trials. *AIDS* **26**, 123.
- 636 18. Gomes, M. G. M., et al. (2014) A missing dimension in measures of vaccination  
637 impacts. *PLOS Pathog.* **10**, e1003849.
- 638 19. Gomes, M. G. M., Gordon, S. B. & Lalloo, D. G. (2016) Clinical trials: the mathematics  
639 of falling vaccine efficacy with rising disease incidence. *Vaccine* **34**, 3007.
- 640 20. Langwig, K. E., et al. (2017) Vaccine effects on heterogeneity in susceptibility and  
641 implications for population health management, *mBio* **8**, e00796-17.
- 642 21. Pessoa, D., et al. (2016) Unveiling time in dose-response models to infer host  
643 susceptibility to pathogens. *PLOS Comput. Biol.* **10**, e1003773.
- 644 22. King, J. G., Souto-Maior, C., Sartori, L. M., Maciel-de-Freitas, R. & Gomes, M. G. M.  
645 (2018) Variation in *Wolbachia* effects on *Aedes* mosquitoes as a determinant of  
646 invasiveness and vectorial capacity. *Nat. Commun.* **9**, 1-8.
- 647 23. Gomes, M. G. M., et al. (2022) Individual variation in susceptibility or exposure to  
648 SARS-CoV-2 lowers the herd immunity threshold. *J. Theor. Biol.* **540**, 111063.
- 649 24. World Health Organization (2021) COVID-19 weekly epidemiological update:  
650 [https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-july-2021)  
651 [13-july-2021](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-july-2021).
- 652 25. Diekmann, O., Heesterbeek, J. A. P. & Metz, J. A. J. (1990) On the definition and  
653 computation of the basic reproduction ratio  $R_0$  in models for infectious diseases in  
654 heterogeneous populations. *J. Math. Biol.* **28**, 365-382.

- 655 26. McAloon, C., et al. (2020) Incubation period of COVID-19: a rapid systematic review  
656 and meta-analysis of observational research. *BMJ Open* **10**, e039652.
- 657 27. Nishiura, H., Linton, N. M. & Akhmetzhanov, A. R. (2020) Serial interval of novel  
658 coronavirus (COVID-19) infections. *Int. J. Infect. Dis.* **93**, 284-6.
- 659 28. Lauer, S. A., et al. (2020) The Incubation Period of Coronavirus Disease 2019 (COVID-  
660 19) From Publicly Reported Confirmed Cases: Estimation and Application. *Ann. Intern.*  
661 *Med.* **172**, 577-582.
- 662 29. Li, Q., et al. (2020) Early transmission dynamics in Wuhan, China, of novel coronavirus-  
663 infected pneumonia. *N. Engl. J. Med.* **382**, 1199-1207.
- 664 30. Wei, W. E., et al. (2020) Presymptomatic Transmission of SARS-CoV-2 — Singapore,  
665 January 23–March 16, 2020. *MMWR Morb. Mortal. Wkly. Rep.* **69**, 411-415.
- 666 31. To, K. K. W., et al. (2020) Temporal profiles of viral load in posterior oropharyngeal  
667 saliva samples and serum antibody responses during infection by SARS-CoV-2: an  
668 observational cohort study. *Lancet Infect. Dis.* **20**, 565-74.
- 669 32. Arons, M. M., et al. (2020) Presymptomatic SARS-CoV-2 Infections and Transmission  
670 in a Skilled Nursing Facility. *N. Engl. J. Med.* **382**, 2081-2090.
- 671 33. He, X., et al. (2020) Temporal dynamics in viral shedding and transmissibility of  
672 COVID-19. *Nat. Med.* **26**, 672-675.
- 673 34. Pastor-Barriuso, R., et al. (2021) SARS-CoV-2 infection fatality risk in a nationwide  
674 seroepidemiological study. *medRxiv* 10.1101/2020.08.06.20169722.
- 675 35. Novozhilov, A. S. (2008) On the spread of epidemics in a closed heterogenous  
676 population. *Math. Biosci.* **215**, 177-185.
- 677 36. Montalbán, A., Corder, R. M. & Gomes, M. G. M. (2022) Herd immunity under  
678 individual variation and reinfection. *J. Math. Biol.* **85**, 2.
- 679 37. Pastor-Satorras, R. & Vespignani, A. (2001) Epidemic dynamics and endemic states in  
680 complex networks. *Phys. Rev. E* **63**, 066117.
- 681 38. Miller, J. C., Slim, A. C. & Volz, E. M. (2012) Edge-based compartmental modelling for  
682 infectious disease spread. *J. R. Soc. Interface* **9**, 890-906.

- 683 39. Britton, T., Ball, F. & Trapman, P. (2020) A mathematical model reveals the influence  
684 of population heterogeneity on herd immunity to SARS-CoV-2. *Science* **369**, 846-849.
- 685 40. Hartnett, K. (2020) The tricky math of herd immunity for COVID-19. *Quanta Magazine*.  
686 [https://www.quantamagazine.org/the-tricky-math-of-covid-19-herd-immunity-](https://www.quantamagazine.org/the-tricky-math-of-covid-19-herd-immunity-20200630/)  
687 [20200630/](https://www.quantamagazine.org/the-tricky-math-of-covid-19-herd-immunity-20200630/)
- 688 41. Aschwanden, C. (2021) Five reasons why COVID herd immunity is probably  
689 impossible. *Nature* **591**, 520-522. <https://www.nature.com/articles/d41586-021-00728-2>
- 690 42. Hall, et al. (2021) SARS-CoV-2 infection rates of antibody-positive compared with  
691 antibody-negative health-care workers in England: a large, multicentre, prospective  
692 cohort study (SIREN). *Lancet* **397**, 1459-1469.
- 693 43. Ferreira, M. L. Mortes por Covid ou com Covid? DGS diz que só entram no boletim  
694 óbitos causados pelo vírus. Como funciona a equipa que tem a última palavra.  
695 *Observador 21 feb 2022*. Available at: [https://observador.pt/especiais/mortes-por-covid-](https://observador.pt/especiais/mortes-por-covid-ou-com-covid-dgs-diz-que-so-entram-no-boletim-obitos-causados-pelo-virus-como-funciona-a-equipa-que-tem-a-ultima-palavra/)  
696 [ou-com-covid-dgs-diz-que-so-entram-no-boletim-obitos-causados-pelo-virus-como-](https://observador.pt/especiais/mortes-por-covid-ou-com-covid-dgs-diz-que-so-entram-no-boletim-obitos-causados-pelo-virus-como-funciona-a-equipa-que-tem-a-ultima-palavra/)  
697 [funciona-a-equipa-que-tem-a-ultima-palavra/](https://observador.pt/especiais/mortes-por-covid-ou-com-covid-dgs-diz-que-so-entram-no-boletim-obitos-causados-pelo-virus-como-funciona-a-equipa-que-tem-a-ultima-palavra/)
- 698 44. Gonçalves, J. Todos os dias há mortes declaradas no boletim da DGS que não foram por  
699 Covid-19”, garante médico infecciosologista. *Rádio Renascença 08 feb 2022*. Available at:  
700 [https://rr.sapo.pt/especial/pais/2022/02/08/todos-os-dias-ha-mortes-declaradas-no-](https://rr.sapo.pt/especial/pais/2022/02/08/todos-os-dias-ha-mortes-declaradas-no-boletim-da-dgs-que-nao-foram-por-covid-19-garante-medico-infecciosologista/271641/)  
701 [boletim-da-dgs-que-nao-foram-por-covid-19-garante-medico-infecciosologista/271641/](https://rr.sapo.pt/especial/pais/2022/02/08/todos-os-dias-ha-mortes-declaradas-no-boletim-da-dgs-que-nao-foram-por-covid-19-garante-medico-infecciosologista/271641/)
- 702 45. Flaxman, S., et al. (2020) Estimating the effects of non-pharmaceutical interventions on  
703 COVID-19 in Europe. *Nature* **584**, 257-261.
- 704 46. Keeling, M. J., et al. (2020) Fitting to the UK COVID-19 outbreak, short-term forecasts  
705 and estimating the reproductive number. *medRxiv* 10.1101/2020.08.04.20163782.
- 706 47. Viana, J. et al. (2021) Controlling the pandemic during the SARS-CoV-2 vaccination  
707 rollout. *Nat. Commun.* **12**, 3674.
- 708 48. Wood, S. N. (2021) Inferring UK COVID-19 fatal infection trajectories from daily  
709 mortality data: Were infections already in decline before the UK lockdowns? *Biometrics*  
710 10.1111/biom.13462.

- 711 49. Tkachenko, A. V., Maslov, S., Elbanna, A., Wong, G. N., Weiner, Z. J. & Goldenfeld,  
712 N. (2021) Time-dependent heterogeneity leads to transient suppression of the COVID-  
713 19 epidemic, not herd immunity. *Proc. Natl. Acad. Sci. U.S.A.* **118**, e2015972118.
- 714 50. Millett, G. A., et al. (2020) Assessing differential impacts of COVID-19 on black  
715 communities. *Ann. Epidemiol.* **47**, 37-44.
- 716 51. Xia, Y., et al. (2022) Concentration of SARS-CoV-2 cases by social determinants of  
717 health in metropolitan areas in Canada: a cross-sectional study. *CMAJ* **194**, E195-E204.
- 718 52. Okonkwo, N. E., et al. (2021) COVID-19 and the US response: accelerating health  
719 inequalities. *BMJ EBM* **26**, 176-179.